Business
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
AcurxPharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced presentation of a scientific poster at the 35th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) held in Munich, Germany from April 17-21, 2026. Dr. Khurshida Begum, Research Scientist, University of Houston College of Pharmacy presented the p
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity","length":141,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Neutropenic CD-1 mice were infected intramuscularly with methicillin-resistant Staphylococcus aureus (MRSA) and subsequently treated with one of three Acurx DNA pol IIIC inhibitors, linezolid, or placebo administered orally","length":223,"tagName":"p"}]},{"val":[{"type":"text","content":"Acurx compounds achieved potentially therapeutic plasma levels and reduced MRSA tissue burden","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Acurx antibiotics maintained a substantially higher gut microbial diversity and a community structure similar to baseline and distinct from linezolid","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Unlike linezolid, ACX compounds maintain Bacteroidota-dominant community structure and prevent Proteobacteria expansion in the gastrointestinal tract ","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"DNA pol IIIC inhibitors demonstrate a class effect of potentially clinically-relevant gut microbiome preservation while demonstrating systemic antibacterial activity","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by CDC","length":185,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":964,"olType":false},{"type":"text","content":"STATEN ISLAND, N.Y., May 4, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced presentation of a scientific poster at the 35th Congress of ESCMID Global (European Society of Clinical Microbiology and Infectious Diseases) held in Munich, Germany from April 17-21, 2026. Dr. Khurshida Begum, Research Scientist, University of Houston College of Pharmacy presented the poster entitled: Preclinical Microbiome Evaluation of Novel PolC-Inhibitor Compounds. Using microbiome profiling shotgun metagenomics (Me...